Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reissue Patent
2008-07-24
2010-02-16
Anderson, Rebecca L (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
Reissue Patent
active
RE041135
ABSTRACT:
The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
REFERENCES:
patent: 4751292 (1988-06-01), Fox
patent: 5397788 (1995-03-01), Horwell et al.
patent: 5622983 (1997-04-01), Horwell et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0133001 (2004-07-01), Waddell et al.
patent: 2005/0245534 (2005-11-01), Link et al.
patent: 2005/0261302 (2005-11-01), Hoff et al.
patent: 2005/0277647 (2005-12-01), Link et al.
patent: 2006/0004049 (2006-01-01), Yao et al.
patent: 2006/0009471 (2006-01-01), Yao et al.
patent: 2006/0009491 (2006-01-01), Yao et al.
patent: 2006/0079506 (2006-04-01), Linders et al.
patent: 2006/0089349 (2006-04-01), Gundertofte et al.
patent: 2006/0094699 (2006-05-01), Kampen et al.
patent: 2006/0100235 (2006-05-01), Andersen et al.
patent: 2006/0106008 (2006-05-01), Andersen et al.
patent: 2006/0106071 (2006-05-01), Lin et al.
patent: 2006/0111348 (2006-05-01), Kampen et al.
patent: 2006/0111366 (2006-05-01), Andersen et al.
patent: 336356 (1989-04-01), None
patent: 405537 (1990-06-01), None
patent: 740752 (1980-09-01), None
patent: 803348 (1981-09-01), None
patent: WO 9113081 (1991-09-01), None
patent: WO 9214697 (1992-09-01), None
patent: WO 9428885 (1994-12-01), None
patent: WO 9500146 (1995-01-01), None
patent: WO 9902145 (1999-01-01), None
patent: WO 0129007 (2001-04-01), None
patent: WO 200365983 (2003-08-01), None
patent: WO 2003-75660 (2003-09-01), None
patent: WO 200411310 (2004-02-01), None
patent: WO 2004033427 (2004-04-01), None
patent: WO 2004037251 (2004-05-01), None
patent: WO 2004056744 (2004-07-01), None
patent: WO 2004056745 (2004-08-01), None
patent: WO 2004065351 (2004-08-01), None
patent: WO 2004089367 (2004-10-01), None
patent: WO 2004089380 (2004-10-01), None
patent: WO 2004089416 (2004-10-01), None
patent: WO 2004089471 (2004-10-01), None
patent: WO 2004089896 (2004-10-01), None
patent: WO 2004978416 (2004-10-01), None
patent: WO 2004989470 (2004-10-01), None
patent: WO 2005016877 (2005-02-01), None
patent: WO 2005042513 (2005-05-01), None
patent: WO 2005046685 (2005-05-01), None
patent: WO 2005047250 (2005-05-01), None
patent: WO 2005060963 (2005-07-01), None
patent: WO 2005097764 (2005-10-01), None
patent: WO 2005103023 (2005-11-01), None
patent: WO 2005108359 (2005-11-01), None
patent: WO 2005116002 (2005-12-01), None
patent: WO 2006002349 (2006-01-01), None
patent: WO 2006002350 (2006-01-01), None
patent: WO 2006002361 (2006-01-01), None
patent: WO 2006012642 (2006-01-01), None
patent: WO 2006012173 (2006-02-01), None
patent: WO 2006012226 (2006-02-01), None
patent: WO 2006012227 (2006-02-01), None
patent: WO 2006017542 (2006-02-01), None
patent: WO 2006020598 (2006-02-01), None
patent: WO 2006024627 (2006-03-01), None
patent: WO 2006024628 (2006-03-01), None
patent: WO 2006040329 (2006-04-01), None
patent: WO 2006048330 (2006-05-01), None
patent: WO 2006048331 (2006-05-01), None
patent: WO 2006048750 (2006-05-01), None
patent: WO 2006049952 (2006-05-01), None
patent: WO 2006050908 (2006-05-01), None
patent: WO 2006053024 (2006-05-01), None
patent: WO 2006066109 (2006-06-01), None
Yau, J., Journal of Neuroscience Lack of tissue Glucocorticoid Reactivation in 11-β-hydrosysteroid Dehydrogenase Type 1 Knockout MiceAmerliorates age-related learning Impairments 98: 4716-4721 (2001).
Goodman and Gillman's, The Pharmacological Basis of Therapeutics, Seventh Edition MacMillan Publishing Company New York, NY (1985). cited by other.
Seck, J.R. et al., Endocrinology Minireview: 11.β.-Hydroxysteroid Dehydrogenase Type 1—A Tissue Specific Amplifier of Glucocorticoid Action 142: 1371-1376 (2001).
Higuchi, T. and Stella, V., Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).
Roche, E., Bioreversible Carriers in Drug Design APA and Pergamon Press (1987).
Jones, C.D. et al., Journal Org. Chem. Effects of Substituent Modification on Face Selection in Reduction 63: 2758-2760 (1998).
Greene, T.W., P.G.M. Wuts “Protective Groups in Organic Synthesis” 3.sup.rd.ed. (1999).
Han et al., J. Am. Chem. Soc. Properly Designed Modular Asymmetric Synthesis for Enantiopure Sulfinamise Auxiliaries fron N-Sulfonyl 1,2,3-oxathiazolidine-2-oxide Agents 124: 7880-7881 (2002).
Walker, B.R. et al., Journal of Clin. Endocrinology and Met. Carbenoxolone increases Hepatic insulin Sensitivity in Man: A Novel Role for 11-Oxosteroid Reductase in Enhancing Glucocorticoid Receptor Activation 80: 3155-3159 (1995).
Billaudel et al., Horm. Metab. Res. Direct Effect of Corticosterone upon Insulin Secretion Studied by Three Different Techniques 11: 555-560 (1979).
Davani et al., Journal of Biol. Chem. Type 1 11.β.-Hydroxysteroid Dehydrogenase Mediates Glucocorticoid Activation and Insulin Release in Pancreatic Islets 275: 34841-34844 (2000).
Paterson, J.M. et al., Proc. Natl. Acad. Sci. USA Metabolic Syndrome without Obesity: Hepatic Overexpression of 11 (β)-hydroxysteroid dehydrogenase type 1 in Transgenic Mice 101: 7088-7093 (2004).
Montague et al., Diabetes, Causes and Consequences of Visceral Adiposity 49: 883-888 (2000).
Orstater et al., Diabetes Metab. Res. Rev. Regulation of 11.β-hydroxysteroid dehydrogenase Type 1 and Glucose-stimulated Insulin Secretion in pancreatic Islets of Langerhans 21: 359-366 (2005).
Masuzaki et al., Science A Transgenic Model of Visceral Obesity and the Metabolic Syndrome 294: 2166-2170 (2001).
Walker, B.R., Clinical Science Corticosteroids and Vascular Tone: Mapping the Messenger Maze 82:597-605 (1992).
Pirpiris, M., Hypertension Pressor Responsiveness in Corticosteroid-Induced Hypertension in Humans 19: 567-574 (1992).
Masuzaki et al., Journal of Clin. Invest. Transgenic Amplification of Glucocorticoid Action in Adipose Tissue Causes High Blood Pressure in Mice 112(1): 83-90 (2003).
Rook, G.A.W., Bailleres Clinical Endocrinology and Metabolism Glucocorticoids and Immune Function 13(4): 567-581 (1999).
Belanoff, J.K., Journal of Psychiatric Research Corticosteroids and Cognition 35: 127:145 (2001).
Baxter, J.D., Pharm. Ther. Glucocorticoid Hormone Action 2: 605-659 (1976).
Bertagna, X., Pituitary Tumors Cushing's Disease Chapter 13 Section 3: 592-612 (2002).
Lupien, S., Nature Cortisol Levels during Human aging Predict Hippocampal Atrophy and memory deficits 1(1): 69-103 (1998).
Stokes, John Invest. Ophthalmology and Vis. Sci. Altered Peripheral Sensitivity to Glucocorticoids in Primary Open-Angle Glaucoma 44(12): 5163-5167 (2003).
Rauz, S., Invest. Ophthalmology and Vis. Science Expression and Putative Rule of 11.β.-Hydroxysteroid Dehdrogenase Isozymes with in the Human Eye 42(9): 2037-2042 (2001).
Wolkowitz, O.M., Annals New York Academy of Sciences The Steroid Dementia Syndrome: An Unrecognized Complication of Glucocorticoid Treatment 1032: 191-194 (2004).
Lane, N., Med Pediatr. Oncol. Effect of Glucocorticoids on Bone Density 41: 212-216 (2003).
Morton, N.M., The Journal of Biological Chem, Improved Lipid and Lipoprotein Profile, Hepatic insulin Sensitivity, and Glucose Tolerance in 11.β.-Hydroxysteroid Dehydrogenase Type 1 Null Mice 276(44): 41293-41300 (2001).
Hermanowski-Vosatka, Journal Exp. Med. 11.β-HSDI Inhibition Ameliorates Metabolic Syndrome and Prevents Progression of Atheroscierosis in Mice 202: 517-527 (2005).
Hammami, M.M., Journal of Clin. Endocrinology Metab. Regulation of 11.β.-Hydroxysteroid Dehydrogenase Activity in Human SkinFibroblasts: enzymatic Modulation of Glucocorticoid Action 73: 326-334 (1991).
Mason, D., Immunology Today Genetic Variation in the Stress Reponse: Susceptibility to Experimental Allergic Encephalomymyelitis and Implications for Human Inflammatory Disease 12(2): 57-60 (1991).
Kornel, L., Steroids M
Kurukulasuriya Ravi
Rohde Jeffrey J.
Sorensen Bryan K.
Abbott Laboratories
Anderson Rebecca L
Vepachedu Sreenivasarao
Young Shawquia
LandOfFree
Inhibitors of the 11-β-hydroxysteroid dehydrogenase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the 11-β-hydroxysteroid dehydrogenase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the 11-β-hydroxysteroid dehydrogenase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183512